These results are consistent with the results of a study by Sini and colleagues, which showed that the Hb level remained stable throughout postoperative whole-pelvis intensity-modulated radiotherapy (IMRT) in prostate cancer patients, and thereafter for at least 1 year, while WBC, ANC, and platelet nadirs occurred at the treatment midpoint, with a similar magnitude of decline, and remained below baseline thereafter [5]. This evidence concerns the gene GSTM1 and Familial prostate cancer.